Canada markets closed

Appili Therapeutics Inc. (APLI.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.0300-0.0050 (-14.29%)
At close: 02:26PM EDT
Full screen
Previous Close0.0350
Open0.0300
Bid0.0300 x N/A
Ask0.0350 x N/A
Day's Range0.0300 - 0.0300
52 Week Range0.0250 - 0.0800
Volume3,004
Avg. Volume91,151
Market Cap3.638M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateNov 11, 2024 - Nov 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

    MOUNTAIN VIEW, Calif., August 29, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024.

  • Business Wire

    Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics

    MOUNTAIN VIEW, Calif., August 21, 2024--Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had entered into a third amending agreement with Appili Therapeutics, Inc. (TSX: APLI; OTCPink: APLIF) ("Appili"), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential b

  • GlobeNewswire

    Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt

    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a third amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adiv